Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-29 pm EDT 5-day change 1st Jan Change
40.25 USD -0.59% Intraday chart for Bristol-Myers Squibb Company -4.94% -21.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer MT
Bristol Myers: new EC approval for Opdivo CF
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
Bristol Myers: will present data on schizophrenia CF
Bristol Myers: presents over 130 studies at ASCO CF
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines MT
Bristol Myers: 10-year strategy for poor countries CF
Bristol-Myers Squibb Invests in NeoPhore MT
Neophore Limited announced that it has received funding from a group of investors CI
Bristol Myers: national schizophrenia campaign CF
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab MT
Bristol Myers: deadline set for subcutaneous Opdivo CF
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (Nivolumab and Hyaluronidase) CI
Everlasting momentum Our Logo
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma DJ
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma MT
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma CI
US FDA approves expanded use of Bristol's cancer cell therapy RE
Transcript : Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Securities Radiopharmaceuticals Day, May-13-2024 11:00 AM
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint MT
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint DJ
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.25 USD
Average target price
53.19 USD
Spread / Average Target
+32.16%
Consensus
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating